InvestorsHub Logo
Followers 1
Posts 6
Boards Moderated 0
Alias Born 02/22/2014

Re: None

Thursday, 09/18/2014 4:03:31 PM

Thursday, September 18, 2014 4:03:31 PM

Post# of 34575
Equity Research released today

I'm on an email list and received this update today. I can forward the info if requested.

John

====

SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data

SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer

==========
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News